Acadia Pharmaceuticals | ACAD - Cost Of Sales



Acadia Pharmaceuticals reported $20.73M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
ALKERMES USD 49.46M 263K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Corcept Therapeutics USD 3.43M 1.03M Jun/2025
Cytokinetics 112.55M 12.71M Jun/2025
Eisai JPY 42.6B 2B Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
J&J USD 7.6B 304M Jun/2025
Moderna USD 119M 29M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Prothena 40.52M 39.55M Jun/2025
PTC Therapeutics USD 15.48M 2.62M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025